<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>中睿医药评论 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-20T20:19:57+08:00</updated>
  <subtitle>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>先声药业引进的1类新药获批临床，针对痛风伴高尿酸血症！</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ozKPzMser7IBCmunOQ6JuA</id>
    <link href="https://mp.weixin.qq.com/s/ozKPzMser7IBCmunOQ6JuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>7款药物纳入第三批临床急需境外新药名单</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ZekMNaIIJ2tJ9a1_us2MDg</id>
    <link href="https://mp.weixin.qq.com/s/ZekMNaIIJ2tJ9a1_us2MDg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」获批上市，首个国产 ALK 抑制剂</title>
    <updated>2020-11-19T17:16:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/lyl6SHl1BZot9SQlBh1rPw</id>
    <link href="https://mp.weixin.qq.com/s/lyl6SHl1BZot9SQlBh1rPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球规模60亿美元，先声药业1.7亿美元引进的CDK 4/6抑制剂临床申请获受理！</title>
    <updated>2020-11-18T17:19:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/RRtl-HmT8jR2pi2CieZWGg</id>
    <link href="https://mp.weixin.qq.com/s/RRtl-HmT8jR2pi2CieZWGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第三十五批参比目录公示：27个新增，15个增补，9个不通过</title>
    <updated>2020-11-18T17:19:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/glX8LstwSgKr_jtqW9SArg</id>
    <link href="https://mp.weixin.qq.com/s/glX8LstwSgKr_jtqW9SArg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州拟赴科创板上市，预计将于2021年上半年完成！</title>
    <updated>2020-11-16T17:22:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/2wfPKNC64ypHf4PqPTESnw</id>
    <link href="https://mp.weixin.qq.com/s/2wfPKNC64ypHf4PqPTESnw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>扬子江「恩替卡韦口服溶液」即将获批</title>
    <updated>2020-11-16T17:22:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/yEDWrh7jjxLmgf8OWh_Zew</id>
    <link href="https://mp.weixin.qq.com/s/yEDWrh7jjxLmgf8OWh_Zew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞、贝达临床试验丨复星疫苗注册受理丨科伦新药注册+仿制药一致性评价</title>
    <updated>2020-11-13T17:25:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/o27zqXp34yJy29d_JW2LWg</id>
    <link href="https://mp.weixin.qq.com/s/o27zqXp34yJy29d_JW2LWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“首仿王”正大天晴再下一城，拿下泊马度胺首仿！</title>
    <updated>2020-11-12T17:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/ILJiJ4r5ikih0R4UdEMqqA</id>
    <link href="https://mp.weixin.qq.com/s/ILJiJ4r5ikih0R4UdEMqqA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森药业「注射用替加环素」首家通过一致性评价</title>
    <updated>2020-11-12T17:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/8QoUIJCeYLySN6KXqOudPg</id>
    <link href="https://mp.weixin.qq.com/s/8QoUIJCeYLySN6KXqOudPg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年销售近 20 亿！科伦药业「丙泊酚中/长链脂肪乳注射液」获批</title>
    <updated>2020-11-11T17:13:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/Ey_3TID54YOF_PMCo8P_-A</id>
    <link href="https://mp.weixin.qq.com/s/Ey_3TID54YOF_PMCo8P_-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>总额 1.39 亿美元！恒瑞 PD-L1/TGF-β 双抗授权给韩国东亚公司</title>
    <updated>2020-11-11T17:13:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/gsChUrMGRDl0dH0aD4V6uw</id>
    <link href="https://mp.weixin.qq.com/s/gsChUrMGRDl0dH0aD4V6uw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2 个 1 类新药已报产，荣昌生物正式在港交所上市</title>
    <updated>2020-11-09T17:31:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/cihue88Nz1S9z0gNljuoig</id>
    <link href="https://mp.weixin.qq.com/s/cihue88Nz1S9z0gNljuoig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>成都赜灵生物引进5款创新药，NLRP3抑制剂、RIP1/2抑制剂等值得关注</title>
    <updated>2020-11-09T17:31:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/vSM0nX4LpG_yuvGHp4FaLw</id>
    <link href="https://mp.weixin.qq.com/s/vSM0nX4LpG_yuvGHp4FaLw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞医药：50周年庆！5000亿市值！一大批创新药在路上！</title>
    <updated>2020-11-06T13:23:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/ndoaC1e4nnOmR-v33yxUKw</id>
    <link href="https://mp.weixin.qq.com/s/ndoaC1e4nnOmR-v33yxUKw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日，百济神州发布第三季度业绩、业务亮点及预计里程碑事件</title>
    <updated>2020-11-06T13:23:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/HEip1hY3gmfkG8v6mwCduA</id>
    <link href="https://mp.weixin.qq.com/s/HEip1hY3gmfkG8v6mwCduA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日，百济神州引进的抗癌新药迪妥昔单抗上市申请获CDE受理</title>
    <updated>2020-11-04T16:51:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/9sWHrLCbBRiCS1FoTUgaTg</id>
    <link href="https://mp.weixin.qq.com/s/9sWHrLCbBRiCS1FoTUgaTg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球销售额15亿美元，青峰药业3类仿制药「拉考沙胺注射液」首家获批</title>
    <updated>2020-11-04T16:51:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/9HtxrTnUTD3ZaOzO5JK-Vw</id>
    <link href="https://mp.weixin.qq.com/s/9HtxrTnUTD3ZaOzO5JK-Vw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>